VIR Vir Biotechnology Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VIR

Price (delayed)

$22.72

Market cap

$3.03B

P/E Ratio

5.84

Dividend/share

N/A

EPS

$3.89

Enterprise value

$2.3B

Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are ...

Highlights
The debt has contracted by 7% YoY and by 2.4% from the previous quarter
VIR's revenue is up by 48% YoY but it is down by 32% from the previous quarter
Vir Biotechnology's equity has increased by 45% YoY but it has decreased by 3.3% from the previous quarter
The price to earnings (P/E) is 64% more than the last 4 quarters average of 3.6
The EPS has dropped by 55% since the previous quarter and by 4.4% year-on-year
Sector: Healthcare
Industry: Biotechnology
Peers: OVID

Key stats

What are the main financial stats of VIR
Market
Shares outstanding
133.53M
Market cap
$3.03B
Enterprise value
$2.3B
Valuations
Price to earnings (P/E)
5.84
Price to book (P/B)
1.46
Price to sales (P/S)
1.86
EV/EBIT
3.04
EV/EBITDA
2.98
EV/Sales
1.42
Earnings
Revenue
$1.62B
EBIT
$754.28M
EBITDA
$769.77M
Free cash flow
$1.6B
Per share
EPS
$3.89
Free cash flow per share
$12.03
Book value per share
$15.61
Revenue per share
$12.18
TBVPS
$20.76
Balance sheet
Total assets
$2.8B
Total liabilities
$724.13M
Debt
$123.84M
Equity
$2.08B
Working capital
$2.01B
Liquidity
Debt to equity
0.06
Current ratio
4.93
Quick ratio
4.73
Net debt/EBITDA
-0.96
Margins
EBITDA margin
47.6%
Gross margin
90.9%
Net margin
31.9%
Operating margin
51.6%
Efficiency
Return on assets
18.8%
Return on equity
25.2%
Return on invested capital
58.7%
Return on capital employed
32.9%
Return on sales
46.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VIR stock price

How has the Vir Biotechnology stock price performed over time
Intraday
-1.35%
1 week
-3.4%
1 month
-15.88%
1 year
-13.94%
YTD
-10.23%
QTD
-10.23%

Financial performance

How have Vir Biotechnology's revenue and profit performed over time
Revenue
$1.62B
Gross profit
$1.47B
Operating income
$833.07M
Net income
$515.84M
Gross margin
90.9%
Net margin
31.9%
The company's operating income has surged by 98% YoY but it fell by 46% QoQ
The net income has dropped by 55% since the previous quarter and by 2.4% year-on-year
VIR's revenue is up by 48% YoY but it is down by 32% from the previous quarter
The company's gross profit rose by 43% YoY but it fell by 33% QoQ

Growth

What is Vir Biotechnology's growth rate over time

Valuation

What is Vir Biotechnology stock price valuation
P/E
5.84
P/B
1.46
P/S
1.86
EV/EBIT
3.04
EV/EBITDA
2.98
EV/Sales
1.42
The price to earnings (P/E) is 64% more than the last 4 quarters average of 3.6
The EPS has dropped by 55% since the previous quarter and by 4.4% year-on-year
Vir Biotechnology's equity has increased by 45% YoY but it has decreased by 3.3% from the previous quarter
VIR's price to book (P/B) is 8% lower than its last 4 quarters average of 1.6
VIR's revenue is up by 48% YoY but it is down by 32% from the previous quarter
The price to sales (P/S) is 18% higher than the last 4 quarters average of 1.6

Efficiency

How efficient is Vir Biotechnology business performance
Vir Biotechnology's return on assets has shrunk by 58% QoQ and by 52% YoY
Vir Biotechnology's return on equity has shrunk by 58% QoQ and by 56% YoY
The return on invested capital has declined by 50% since the previous quarter and by 45% year-on-year
The return on sales has declined by 23% since the previous quarter and by 7% year-on-year

Dividends

What is VIR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VIR.

Financial health

How did Vir Biotechnology financials performed over time
Vir Biotechnology's total assets has increased by 43% YoY and by 3.9% QoQ
The company's total liabilities rose by 39% YoY and by 33% QoQ
The debt is 94% less than the equity
Vir Biotechnology's equity has increased by 45% YoY but it has decreased by 3.3% from the previous quarter
The debt to equity fell by 33% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.